Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.
This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents
In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.
Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.
Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.
ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels
CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.
EPCCS 2018 A recording of the lecture by Prof. Cos on the evidence fro diabetes and accelerated vascular disease, and which interventions can change this relationship.
Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.
ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.